An upgraded bednet prevented 13 million malaria cases and saved 24,600 lives

By David Ogilvy, Chief Marketing Officer at Mosticare Global | Published 2026-06-10

The most consequential anti-malaria tool of the last few years is not a vaccine, a gene drive or an app. It is a bednet — the same humble object that has hung over beds for a century — with one important difference. Someone added a second poison. That single change is credited with preventing roughly 13 million malaria cases and saving 24,600 lives between 2019 and 2022.

The net is called Interceptor G2, and its story is a quiet rebuke to the assumption that progress always means complexity. For two decades the insecticide-treated net was the workhorse of malaria control, and it worked extraordinarily well — until the mosquitoes caught up.

The problem the old net could not solve

Conventional bednets are treated with pyrethroids, a class of insecticide that for years killed mosquitoes reliably and cheaply. The difficulty is the oldest one in biology. Use a single poison widely enough, for long enough, and you select for the rare individuals that survive it. Across much of sub-Saharan Africa, pyrethroid resistance spread through Anopheles mosquito populations until the standard net was, in many places, little more than a physical curtain — useful, but no longer doing the chemical work it was designed for.

This is the resistance trap, and it has no shortcut. You cannot out-spray it. The only durable answer is to attack the mosquito by a different mechanism, one its resistance has not yet been built to defeat.

What changed

Interceptor G2 combines the familiar pyrethroid with a second active ingredient: chlorfenapyr. The two work in entirely different ways. Where the pyrethroid attacks the nervous system, chlorfenapyr is, in effect, an energy-sapping compound — it disrupts the mosquito's ability to produce the energy its cells need, killing even insects that shrug off the pyrethroid. A mosquito resistant to one is not automatically resistant to the other. Two locks are harder to pick than one.

The chemistry was the easy part. The chemical company BASF spent the better part of a decade in the laboratory not inventing chlorfenapyr — it already existed — but solving the unglamorous engineering problem of making it work on a net. The compound had to bind to fabric and stay there for three years of rubbing and washing without degrading, and it had to be safe enough to lie inches from a sleeping infant's face all night. That is a far harder brief than killing a mosquito in a Petri dish, and it is where the real innovation lived.

The evidence

The proof came from field trials, not press releases. Medical entomologist Corine Ngufor, an associate professor at the London School of Hygiene & Tropical Medicine, led randomised evaluations in Benin — in Cotonou and Covè — and the results were stark. In settings like these and in Mozambique, the new net cut malaria rates by roughly half. As the Gates Foundation summarised it, the dual-ingredient net proved "twice as effective at protecting children from getting malaria than the old nets."

Those are the words that matter most, because malaria is overwhelmingly a disease of children. Halving the rate is not a marginal gain. It is the difference between a manageable season and an overwhelmed clinic.

Turning a trial result into 13 million prevented cases required a second, less celebrated kind of work: getting the nets out at a price countries could afford. The first 35 million Interceptor G2 nets were delivered in 2019, coordinated through the Innovative Vector Control Consortium with financing arrangements — including a role for the access-finance organisation MedAccess — designed to drive the cost down and the volume up. Tom McLean of the IVCC and his colleagues treated affordability as part of the product, not an afterthought. A net that works in a trial but is too expensive to deploy saves nobody.

Why this is the right kind of lesson

It is tempting, in a field crowded with gene drives and engineered mosquitoes, to treat a better bednet as a footnote. That would be a mistake. The Interceptor G2 story carries a principle worth holding onto: the most powerful intervention is often the proven one, improved — not the newest one, unproven.

A net poisons nothing beyond the mosquito that lands on it. It needs no cold chain, no clinic, no electricity and no second dose. It works while you sleep, costs a few pounds, and lasts years. Layer it with the other measures that have driven dengue down 75% in Brazil and suppressed mosquito populations in Singapore — source reduction, sterile-insect releases, surveillance — and you have a defence that does not depend on any single technology holding the line.

For Europe, where the conversation is about the tiger mosquito moving north rather than malaria, the transferable lesson is the same. The barrier between you and the bite is still the most reliable protection there is, and a treated net over the bed remains the gold standard the World Health Organization recommends for exactly this reason. The technology that halved malaria in Mozambique and the net over a bed in Lyon are closer cousins than they look.

What to watch next

Resistance does not retire; it adapts. The mosquitoes that learned to survive pyrethroids will, in time, meet chlorfenapyr widely enough to begin the same slow selection again — which is why the people behind these nets are already working on third and fourth active ingredients to keep the rotation ahead of the insect. The race is permanent. The encouraging news from 2019 to 2022 is that, for now, the humble bednet is winning it — and that the unfashionable business of making an old tool work better may be the most valuable innovation in the room.

What we know

Sources cited

1. Gates Foundation — A new mosquito net is saving lives from malaria (2026). https://www.gatesfoundation.org/ideas/articles/new-mosquito-net-saving-lives-malaria